A randomized, double-blind, active-controlled trial assessing the efficacy and safety of a fixed-dose combination (FDC) of MEtformin hydrochloride 1000 mg ER, SItagliptin phosphate 100 mg, and DApagliflozin propanediol 10 mg in Indian adults with type 2 diabetes: The MESIDA trial
ConclusionFDC of DSM was superior to SM in reducing HbA1c, FPG, and PPG in Indian adults with T2D. Both triple and dual FDCs had optimal safety profiles. (Source: International Journal of Diabetes in Developing Countries)
Source: International Journal of Diabetes in Developing Countries - February 17, 2024 Category: Endocrinology Source Type: research
Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study)
CONCLUSIONS: This comparative effectiveness study of a contemporary cohort of adults with type 2 diabetes, largely without established cardiovascular disease, suggests that liraglutide treatment may reduce the risk of cardiovascular events in patients at relatively low risk compared with other commonly used glucose-lowering medications.REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01794143.PMID:38344820 | DOI:10.1161/CIRCULATIONAHA.123.066604 (Source: Circulation)
Source: Circulation - February 12, 2024 Category: Cardiology Authors: Jennifer B Green Brendan M Everett Alokananda Ghosh Naji Younes Heidi Krause-Steinrauf Joshua Barzilay Cyrus Desouza Silvio E Inzucchi Yashashwi Pokharel David Schade Alexandra Scrymgeour Meng H Tan Kristina M Utzschneider Sunder Mudaliar GRADE Study Rese Source Type: research
Biochemical evaluation and ligand binding studies on glycerophosphodiester phosphodiesterase from Staphylococcus aureus using STD-NMR spectroscopy and molecular docking analysis
In this study, competent E. coli BL21(DE3)pLysS expression cells were used to express the GDPD enzyme from vancomycin-resistant Staphylococcus aureus (VRSA), which was then purified using size exclusion and anion exchange chromatography. The hydrolytic activity of GDPD was evaluated on the non-physiological substrate bis(p-nitrophenyl) phosphate (BpNPP), which indicated functional activity of the enzyme. 79 drugs were evaluated for their inhibitory potential against GDPD enzyme by the colorimetric assay. Out of 79 drugs, 13 drugs, including tenofovir (1), adenosine (2), clioquinol (11), bromazepam (12), lamotrigine (13), s...
Source: Bioorganic Chemistry - February 9, 2024 Category: Chemistry Authors: Uzma Salar None Atia-Tul-Wahab M Iqbal Choudhary Source Type: research
Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Na ïve Type 2 Diabetes Mellitus Patients
CONCLUSION: Initial triple combination therapy with metformin, sitagliptin, and empagliflozin led to achievement of the glycemic target goal, which was maintained for 24 months without severe hypoglycemia but with improved metabolic function and albuminuria. This combination therapy may be a good strategy for drug-naïve patients with type 2 diabetes mellitus.PMID:38273791 | DOI:10.4093/dmj.2023.0128 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - January 26, 2024 Category: Endocrinology Authors: Young-Hwan Park Minji Sohn So Yeon Lee Soo Lim Source Type: research
Low dose sulphonylurea plus DPP4 inhibitor lower blood glucose and enhance beta cell function without hypoglycaemia
CONCLUSIONS: Low dose sulphonylurea plus DPP4i has potent glucose lowering effect through augmentation of beta cell function. A double-blind randomised controlled trial would formalise efficacy and safety of this combination, which may avoid negative aspects of SU.PMID:38267622 | DOI:10.1210/clinem/dgae033 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - January 24, 2024 Category: Endocrinology Authors: Ruth Lorna Mary Cordiner Khaled Bedair Andrea Mari Ewan Pearson Source Type: research
Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin as Metformin Add-on in a Korean Population with Type 2 Diabetes
ConclusionThis analysis confirms efficacy and safety of OW semaglutide (0.5 and 1.0 mg) in a Korean population with T2D.Clinical Trial Registration NumberNCT03061214. (Source: Diabetes Therapy)
Source: Diabetes Therapy - January 18, 2024 Category: Endocrinology Source Type: research
Combination of spironolactone and sitagliptin improves clinical outcomes of outpatients with COVID-19: a prospective cohort study
ConclusionsThe combination of sitagliptin and spironolactone reduced duration of COVID infection and hospital visits better than standard therapeutic approaches in outpatients with COVID-19. The effects of combination of sitagliptin and spironolactone in COVID-19 patients should be further verified in a double-blind, randomized, placebo-controlled trial. (Source: Journal of Endocrinological Investigation)
Source: Journal of Endocrinological Investigation - January 1, 2024 Category: Endocrinology Source Type: research
Effect of Chiglitazar and Sitagliptin on Bone Mineral Density and Body Composition in Untreated Patients with Type 2 Diabetes
(Source: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy)
Source: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy - December 27, 2023 Category: Endocrinology Tags: Diabetes, Metabolic Syndrome and Obesity Source Type: research
Increased Thyroid DPP4 Expression is Associated with Inflammatory Process in Patients with Hashimoto's Thyroiditis
CONCLUSIONS: The DPP4 expression was significantly increased in the thyroid of the HT group than in the control group, and mainly localized in the lymphocytes. Inhibition of lymphocyte DPP4 activity reduced the production of inflammatory factors in co-cultured thyroid cells. Therefore, inhibition of DPP4 may have a beneficial effect by alleviating inflammatory reactions in HT patients.PMID:38127960 | DOI:10.1210/clinem/dgad723 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - December 21, 2023 Category: Endocrinology Authors: Xiaohui Wen Xiaona Chang Xueqing He Qingyun Cai Guang Wang Jia Liu Source Type: research
Retraction notice to "Ameliorative potential of sitagliptin and/or resveratrol on experimentally-induced clear cell renal cell carcinoma" [Biomed. Pharmacother. 97 (2017) 667-674
Biomed Pharmacother. 2023 Dec 20:116048. doi: 10.1016/j.biopha.2023.116048. Online ahead of print.NO ABSTRACTPMID:38129205 | DOI:10.1016/j.biopha.2023.116048 (Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie)
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - December 21, 2023 Category: Drugs & Pharmacology Authors: Ahmed M Kabel Aliaa Atef Remon S Estfanous Source Type: research
Increased Thyroid DPP4 Expression is Associated with Inflammatory Process in Patients with Hashimoto's Thyroiditis
CONCLUSIONS: The DPP4 expression was significantly increased in the thyroid of the HT group than in the control group, and mainly localized in the lymphocytes. Inhibition of lymphocyte DPP4 activity reduced the production of inflammatory factors in co-cultured thyroid cells. Therefore, inhibition of DPP4 may have a beneficial effect by alleviating inflammatory reactions in HT patients.PMID:38127960 | DOI:10.1210/clinem/dgad723 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - December 21, 2023 Category: Endocrinology Authors: Xiaohui Wen Xiaona Chang Xueqing He Qingyun Cai Guang Wang Jia Liu Source Type: research
Anti-inflammatory and antinociceptive effects of sitagliptin in animal models and possible mechanisms involved in the antinociceptive activity
CONCLUSIONS: : NO/cGMP/KATP, 5HT3 and D2 pathways play an important role in the antinociceptive effect of sitagliptin. Additionally significant anti-inflammatory effects observed in the carrageenan test might contribute in reduction of pain response in the second phase of the formalin test.PMID:38123184 | DOI:10.3344/kjp.23262 (Source: Korean Journal of Pain)
Source: Korean Journal of Pain - December 20, 2023 Category: Anesthesiology Authors: Valiollah Hajhashemi Hossein Sadeghi Fatemeh Karimi Madab Source Type: research
Efficacy and safety of teneligliptin in patients with type 2 diabetes mellitus: a Bayesian network meta-analysis
ConclusionCompared to sitagliptin, vildagliptin, metformin, bromocriptine, and placebo, teneligliptin displayed favorable efficacy and acceptable safety in treating T2DM. Twenty milligrams or 40 mg per day was the optimal dosage regimen of teneligliptin. The results of this study will provide important evidence-based basis for rational use of teneligliptin and clinical decision-making of T2DM medication. (Source: Frontiers in Endocrinology)
Source: Frontiers in Endocrinology - December 18, 2023 Category: Endocrinology Source Type: research
